Transition states and inhibitors of the purine nucleoside phosphorylase family

Current Topics in Medicinal Chemistry

Volumn 5, Issue 13, 2005, Pages 1237-1258

  Taylor Ringia, Erika A ^a   Schramm, Vern L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

DADMe Immucillin; Immucillin; Inhibitor; Kinetic isotope effects; Malaria; Purine nucleoside phosphorylase; T cell disorders; Transition state analogue

Indexed keywords

2' DEOXYIMMUCILLIN G; 3' DEOXYIMMUCILLIN H; 5' DEOXYIMMUCILLIN H; 6 THIOIMMUCILLIN H; 8 AZAIMMUCILLIN H; 9 (1' METHYL)IMMUCILLIN H; 9 DEAZAINOSINE; ENZYME INHIBITOR; IMMUCILLIN A; IMMUCILLIN G; IMMUCILLIN H; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG;

COW; CRYSTALLOGRAPHY; DRUG STRUCTURE; DRUG SYNTHESIS; ENERGY CONVERSION; ENZYME BINDING; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMODIUM FALCIPARUM; PREDICTION; REVIEW;

ANIMALS; BINDING SITES; CATALYSIS; ENZYME INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; PLASMODIUM FALCIPARUM; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINONES; PYRROLIDINES; SEQUENCE ALIGNMENT; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29444445067     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802605774463088     Document Type: Review

References (79)

1. Levene, P. A.; Medigreceanu, F. On Nucleases. J. Biol. Chem., 1911, 9, 65-83.
2. Kalckar H. M. The Enzymatic Synthesis of a Nucleoside. J. Biol. Chem., 1945, 158, 723-724.
3. Schramm, V. L. Development of Transition State Analogues of Purine Nucleoside Phosphorylase as Anti-T-Cell Agents. Biochim. Biophys. Acta, 2002, 1587, 107-117.
4. Giblett, E. R.; Ammann, A. J.; Wara, D. W.; Sandman, R.; Diamond, L. K. Nucleoside-Phosphorylase Deficiency in a Child With Severely Defective T-Cell Immunity and Normal B-Cell Immunity. Lancet, 1975, 1, 1010-1013.
5. Sherman, I. W. Transport of Amino Acids and Nucleic Acid Precursors in Malarial Parasites. Bull. W.H.O., 1977, 55, 211-225.
6. Koenigk, E. Salvage Syntheses and Their Relationship to Nucleic Acid Metabolism. Bull. W.H.O., 1977, 55, 249-252.
7. Sherman, I. W. Biochemistry of Plasmodium. Microbiol. Rev., 1979, 43, 453-495.
8. Hughes, B. W.; King, S. A.; Allan, P. W.; Parker, W. B.; Sorscher, E. J. Cell to Cell Contact Is Not Required for Bystander Cell Killing by Escherichia coli Purine Nucleoside Phosphorylase. J. Biol. Chem., 1998, 273, 2322-2328.
9. Niculescu-Duvaz, I.; Spooner, R.; Marais, R.; Springer, C. J. Gene-Directed Enzyme Prodrug Therapy. Bioconjugate Chem., 1998, 9, 4-22.
10. Kazmers, I. S.; Mitchell, B. S.; Dadonna, P. E.; Wotring, L. L.; Townsend, L. B.; Kelley, W. N. Inhibition of Purine Nucleoside Phosphorylase by 8-Aminoguanosine: Selective Toxicity for T Lymphoblasts. Science, 1981, 214, 1137-1139.
11. Parks, R. E.; Stoeckler, J. D.; Cambor, C.; Savarese, T. M.; Crabtree, G. W.; Chu, S. H. Purine Nucleoside Phosphorylase and 5′-Methylthioadenosine Phosphorylase: Targets for Chemotherapy. In Molecular Actions and Targets for Cancer Chemotherapeutic Agents; Sartorelli, A.; Lazo, J. S.; Bertino, J. R. Eds.; Academic Press: New York, 198 1: pp. 229-252.
12. Stoeckler, J. D. Purine Nucleoside Phosphorylase: A Target for Chemotherapy. In Developments in Cancer Chemotherapy; Glazer, R. J. Ed.; CRC Press: Boca Raton, 1984: pp. 35-60.
13. Kredich, N. M.; Hershfield, M. S. Immunodeficiency Diseases Caused by Adenosine Deaminase Deficiency and Purine Nucleoside Phosphorylase Deficiency. In The Metabolic Basis of Inherited Disease 6th Edition; Stanbury, J. B.; Wyngaarden, J. B.; Fredrickson, D. S. Eds.; McGraw-Hill: New York, 1989: pp. 1045-1075.
14. Hilman, B. C.; Sorensen, R. U. Management Options - SCIDs with Adenosine Deaminase Deficiency. Ann. Allergy, 1994, 72, 395-403.
15. Morris, P. E.; Montgomery, J. A. Inhibitors of the Enzyme Purine Nucleoside Phosphorylase. Expert Opin. Ther. Pat., 1998, 8, 283-299.
16. Bzowska, A.; Kulikowska, E.; Shugar, D. Purine Nucleoside Phosphorylases: Properties, Functions, and Clinical Aspects. Pharmacol. Therapeut., 2000, 88, 349-425.
17. Douglas, J. T., Cancer Gene Therapy. Tech. Cancer Res. T., 2003, 2, 51-63.
18. Bantia, S.; Kilpatrick, J. M. Purine Nucleoside Phosphorylase Inhibitors in T-Cell Malignancies. Curr. Opin. Drug Disc., 2004, 7, 243-247.
19. Barreiro, P.; Garcia-Benayas, T.; Rendon, A.; Rodriguez-Novoa, S.; Soriano, V. Combinations of Nucleoside/Nucleotide Analogues for HIV Therapy. AIDS Rev., 2004, 6, 234-243.
20. Mehlin, C. Structure-Based Drug Discovery for Plasmodium falciparum. Comb. Chem. High T. Scr., 2005, 8, 5-14.
21. Parks, R. E.; Agarwal, R. P. Purine Nucleoside Phosphorylase. Enzymes, 1972, 7, 483-514.
22. Morris, P. E.; Omura, G. A. Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis. Curr. Pharm. Design, 2000, 6, 943-959.
23. Pugmire, M. J.; Ealick, S. E. Structural Analyses Reveal Two Distinct Families of Nucleoside. Biochem. J., 2002, 361, 1-25.
24. Zoltewicz, J. A.; Clark, D. F.; Sharpless, T. W.; Grahe, G. Kinetics and Mechanism of The Acid-Catalyzed Hydrolysis of Some Purine Nucleosides. J. Amer. Chem. Soc., 1970, 92, 1741-1750.
25. Kim, B. K.; Cha, S.; Parks, R. E. Purine Nucleoside Phosphorylase from Human Erythroyctes. II. Kinetic Analysis and Substrate-Binding Studies. J. Biol. Chem., 1968, 243, 1771-1776.
26. Lewis, A. S.; Glantz, M. D. Bovine Brain Purine-Nucleoside Phosphorylase Purification, Characterization, and Catalytic Mechanism. Biochemistry, 1976, 15, 4451-4456.
27. Kline, P. C.; Schramm, V. L. Purine Nucleoside Phosphorylase. Inosine Hydrolysis, Tight Binding of the Hypoxanthine Intermediate, and Third-The-Sites Reactivity. Biochemistry, 1992, 31, 5964-5973.
28. Krenitsky, T., Purine Nucleoside Phosphorylase: Kinetics, Mechanism, and Specificity. Mol. Pharmacol., 1967, 3, 526-536.
29. Carlson, J. D.; Fischer, A. G. Characterization of the Active Site of Homogeneous Thyroid Purine Nucleoside Phosphorylase. Biochim. Biophys. Acta, 1979, 571, 21-34.
30. Ealick, S. E.; Rule, S. A.; Carter, D. C.; Greenhough, T. J.; Babu, Y. S.; Cook, W. J.; Habash, J.; Helliwell, J. R.; Stoeckler, J. D.; Parks, R. E. Three-Dimensional Structure of Human Erythrocytic Purine Nucleoside Phosphorylase at 3.2 Å Resolution. J. Biol. Chem., 1990, 265, 1812-1820.
31. Erion, M. D.; Takabayashi, K.; Smith, H. B.; Kessi, J.; Wagner, S.; Hoenger, S.; Shames, S. L.; Ealick, S. E. Purine Nucleoside Phosphorylase. 1. Structure-Function Studies. Biochemistry, 1997, 36, 11725-11734.
32. Erion, M. D.; Stoeckler, J. D.; Guida, W. C.; Walter, R. L.; Ealick, S. E. Purine Nucleoside Phosphorylase. 2. Catalytic Mechanism. Biochemistry, 1997, 36, 11735-11748.
33. Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L. One-Third-The-Sites Transition-State Inhibitors for Purine Nucleoside Phosphorylase. Biochemistry, 1998, 37, 8615-8621.
34. Mao, C.; Cook, W. J.; Zhou, M.; Fedorov, A. A.; Almo, S. C.; Ealick, S. E. Calf Spleen Purine Nucleoside Phosphorylase Complexed with Substrates and Substrate Analogues. Biochemistry, 1998, 37, 7135-7146.
35. Jensen, K. F.; Nygaard, P. Purine Nucleoside Phosphorylase from Escherichia coli and Salmonella typhimurium. Purification and Some Properties. Eur. J. Biochem., 1975, 51, 253-265.
36. Jensen, K. F. Purine-Nucleoside Phosphorylase from Salmonella typhimurium and Escherichia coli. Initial Velocity Kinetics, Ligand Banding, and Reaction Mechanism. Eur. J. Biochem., 1976, 61, 377-386.
37. Stein R. L.; Cordes, E. H. Kinetic Alpha-Deuterium Isotope Effects for Escherichia coli Purine Nucleoside Phosphorylase-Catalyzed Phosphorolysis of Adenosine and Inosine. J. Biol. Chem., 1981, 256, 767-772.
38. Bennett, E. M.; Li, C. L.; Allan, P. W.; Parker, W. B.; Ealick, S. E. Structural Basis for Substrate Specificity of Escherichia coli Purine Nucleoside Phosphorylase. J. Biol. Chem., 2003, 278, 47110-47118.
39. Kierdaszuk, B.; Modrak-Wójcik, A.; Wierzchowski, J.; Shugar, D. Formycin A and Its N-Methyl Analogues, Specific Inhibitors of E. coli Purine Nucleoside Phosphorylase (PNP): Induced Tautomeric Shifts on Binding to Enzyme and Enzyme → Ligand Fluorescence Resonance Energy Transfer. Biochim. Biophys. Acta., 2000, 1476, 109-128.
40. Koellner, G.; Bzowska, A.; Wielgus-Kutrowska, B.; Luic, M.; Steiner, T.; Saenger, W.; Stepikski, J. Open and Closed Conformation of the E. coli Purine Nucleoside Phosphorylase Active Center and Implications for the Catalytic Mechanism. J. Mol. Biol., 2002, 315, 351-371.
41. Koellner, G.; Luic, M.; Shugar, D.; Saenger, W.; Bzowska, A. Crystal Structure of the Ternary Complex of E. coli Purine Nucleoside Phosphorylase with Formycin B, a Structural Analogue of the Substrate Inosine, and Phosphate (Sulphate) at 2.1 Å Resolution. J. Mol. Biol., 1998, 280, 153-166.
42. Shi, W. X.; Ting, L.-M.; Kicska, G. A.; Lewandowicz, A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Kim, K.; Almo, S. C.; Schramm, V. L. Plasmodium falciparum Purine Nucleoside Phosphorylase: Crystal Structures, Immucillin Inhibitors and Dual Catalytic Function. J. Biol. Chem., 2004, 279, 18103-18106.
43. Wolfenden R.; Snider, M. J. Testing the Limits of Protein-Ligand Binding Discrimination with Transition-State Analogue Inhibitors. Acc. Chem. Res., 2001, 34, 938-945.
44. Schramm, V. L. Enzymatic Transition States and Transition State Analog Design. Ann. Rev. Biochem., 1998, 67, 693-720.
45. Schramm, V. L. Enzymatic Transition-State Analysis and Transition State Analogs. Method Enzymol., 1999, 308, 301-355.
46. Cleland, W. W. The Use of Isotope Effects to Determine Transition-State Structure for Enzymatic Reactions. Method Enzymol., 1982, 87, 625-641.
47. Cleland, W. W. Isotope Effects: Determination of Enzyme Transition State Structure. Method Enzymol., 1995, 249, 341-373.
48. Radzicka, A.; Wolfenden, R. A Proficient Enzyme. Science, 1995, 267, 90-93.
49. Bruice, T. C.; Benkovic, S. J. Chemical Basis for Enzyme Catalysis. Biochemistry, 2000, 39, 6267-6274.
50. Taylor, E. A.; Palmer, D. R. J.; Gerlt, J. A. The Lesser "Burden Bourne" by o-Succinylbenzoate Synthesis: An "Easy" Reaction Involving a Carboxylate Carbon Acid. J. Amer. Chem. Soc., 2001, 123, 5824-5825.
51. Suehnel, J.; Schowen, R. L. Theoretical Basis for Primary and Secondary Isotope Effects. In Enzyme Mechanism from Isotope Effects; Cook, P. F. Ed.; CRC Press: Boca Raton, 1990: pp 3-35.
52. Schramm, V. L. Enzymatic Transition States: Thermodynamics, Dynamics and Analogue Design. Arch. Biochem. Biophys., 2005, 433, 13-26.
53. Kline, P. C.; Schramm, V. L. Purine Nucleoside Phosphorylase. Catalytic Mechanism and Transition-State Analysis of the Arsenolysis Reaction. Biochemistry, 1993, 32, 13212-13219.
54. Kline, P. C.; Schramm, V. L. Pre-Steady-State Transition-State Analysis of the Hydrolytic Reaction Catalyzed by Purine Nucleoside Phosphorylase. Biochemistry, 1995, 34, 1153-1162.
55. Sims, L. B.; Burton, G. W.; Lewis, D. E. Quantum Chemistry Program Exchange, 1977, No 337, Indiana University: Bloomington.
56. Kicska, G. A.; Long, L.; Horig, H.; Fairchild, C.; Tyler, P. C; Furneaux, R. H.; Schramm, V. L.; Kaufman, H. L. Immucillin H, a Powerful Transition-State Analog Inhibitor of Purine Nucleoside Phosphorylase, Selectively Inhibits Human T Lymphocytes. Proc. Nat. Acad. Sci., 2001, 98, 4593-4598.
57. Bantia, S.; Miller, P. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Babu, Y. S.; Sandhu, J. S. Purine Nucleoside Phosphorylase Inhibitor BCX-1777 (Immucillin-H)--A Novel Potent and Orally Active Immunosuppressive Agent. Int. Immunopharmacol., 2002, 2, 913-923.
58. Lewandowicz, A.; Schramm, V. L. Transition State Analysis for Human and Plasmodium falciparum Purine Nucleoside Phosphotylases. Biochemistry, 2004, 43, 1458-1468.
59. Krudsood, S.; Buchachart, K,; Charusabha, C.; Treeprasertsuk, S.; Haoharn, O.; Duangdee, C.; Looareesuwan, S. A Comparative Clinical Trial of Combinations of Dihydroartemisinin plus Azithromycin and Dihydroartemisinin plus Mefloquine for Treatment of Multidrug Resistant Falciparum Malaria. Southeast Asian J. Trop. Med. Pub. Health, 2002, 33, 525-531.
60. Whitty, C. J. M.; Sanderson, F. New Therapies and Changing Patterns of Treatment for Malaria. Curr. Opin. Infect. Dis., 1999, 12, 579-584.
61. Queen, S. A.; Jagt, D. L.; Reyes, P. In Vitro Susceptibilities of Plasmodium falciparum to Compounds Which Inhibit Nucleotide Metabolism. Antimicrob. Agents Chemother., 1990, 34, 1393-1398.
62. Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Kim, K.; Schramm, V. L. Transition State Analogue Inhibitors of Purine Nucleoside Phosphorylase from Plasmodium falciparum. J. Biol. Chem., 2002, 277, 3219-3225.
63. Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L.; Kim, K. Purine-Less Death in Plasmodium falciparum Induced by Immucillin-H, a Transition State Analogue of Purine Nucleoside Phosphorylase. J. Biol. Chem., 2002, 277, 3326-3231.
64. Chen, X.-Y.; Berti, P. J.; Schramm, V. L. Transition-State Analysis for Depurination of DNA by Ricin A-Chain. J. Amer. Chem. Soc., 2000, 122, 1609-1617.
65. Berti, P. J.; Tanaka, K. S. E. Transition State Analysis Using Multiple Kinetic Isotope Effects: Mechanisms of Enzymatic and Non-Enzymatic Glycoside Hydrolysis and Transfer. Adv. Phys. Org. Chem., 2002, 37, 239-314.
66. Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Shi, W. X.; Fedorov, A. A.; Lewandowicz, A.; Cahill, S. M.; Almo, S. C.; Schramm, V. L. Atomic Dissection of the Hydrogen Bond Network for Transition-State Analogue Binding to Purine Nucleoside Phosphorylase. Biochemistry, 2002, 41, 14489-14498.
67. Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; Tyler, P. C. Exploring Structure-Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase. J. Med. Chem., 2003, 46, 3412-3423.
68. Lewandowicz, A.; Taylor Ringia, E. A.; Ting, L.-M.; Kim, K.; Tyler, P. C.; Evans, G. B.; Zubkova, O. V.; Mee, S.; Painter, G. P.; Lenz, D. H.; Furneaux, R. H.; Schramm, V. L. Transition State Analogue Specificity for Human and Plasmodium falciparum Purine Nucleoside Phosphorylase. J. Biol. Chem., 2005, 280, 30320-30328.
69. Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; Tyler, P. C. Synthesis of Second-Generation Transition State Analogues of Human Purine Nucleoside Phosphorylase. J. Med. Chem., 2003, 46, 5271-5276.
70. Lewandowicz, A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L. Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase. J. Biol. Chem., 2003, 278, 31465-31468.
71. Bantia, S.; Miller, P. J.; Parker, C. D.; Ananth, S. L.; Hom, L. L.; Babu, Y. S.; Sandhu, J. S. Purine Nucleoside Phosphorylase Inhibitor BCX-1777 (Immucillin-H)--A Novel Potent and Orally Active Immunosuppressive Agent. Int. Immunopharmacol., 2002, 2, 913-923.
72. Ting, L.-M.; Shi, W. X.; Lewandowicz, A.; Singh, V.; Mwakingwe, A.; Birck, M. R.; Taylor Ringia, E. A.; Bench, G.; Madrid, D. C.; Tyler, P. C.; Evans, G. B.; Furricaux, R. H.; Schramm, V. L.; Kim, K. Targeting a Novel Plasmodium falciparum Purine Recycling Pathway with Specific Immucillins. J. Biol. Chem., 2005, 280, 9547-9554.
73. Basso, L. A.; Santos, D. S.; Shi, W. X; Furneaux, R. H.; Tyler, P. C.; Schramm, V. L; Blanchard, J. S. Purine Nucleoside Phosphorylase from Mycobacterium tuberculosis. Analysis of Inhibition by a Transition-State Analogue and Dissection by Parts. Biochemistry, 2001, 40, 8196-8203.
74. Lewandowicz, A.; Shi, W. X.; Evans, G. B.; Tyler, P. C.; Furneaux, R. H.; Basso, L. A.; Santos, D. S.; Almo, S. C.; Schramm, V. L. Over-the-Barrier Transition State Analogues and Crystal Structure with Mycobacterium tuberculosis Purine Nucleoside Phosphorylase. Biochemistry, 2003, 42, 6057-6066.
75. Schramm, V. L. Enzymatic Transition State Poise and Transition State Analogues. Acc. Chem. Res., 2003, 36, 588-596.
76. Núñez, S.; Antoniou, D.; Schramm, V. L.; Schwartz, S. D. Electronic Promoting Motions in Human Purine Nucleoside Phosphorylase: A Molecular Dynamics and Hybrid Quantum Mechanical/Molecular Mechanical Study. J. Amer. Chem. Soc., 2004, 126, 15720-15729.
77. Shi, W.; Basso, L. A.; Santos, D. S.; Tyler, P. C.; Furneaux, R. H.; Blanchard, J. S.; Almo, S. C.; Schramm, V. L. Structures of Purine Nucleoside Phosphorylase from Mycobacterium tuberculosis in Complexes with Immucillin-H and Its Pieces. Biochemistry, 2001, 40, 8204-8215.
78. Fedorov, A.; Shi, W.; Kicska, G. A.; Fedorov, E.; Tyler, P. C.; Furneaux, R. H.; Hanson, J. C.; Gainsford, G. J.; Larese, J. Z.; Schramm, V. L.; Almo, S. C. Transition State Structure of Purine Nucleoside Phosphorylase and Principles of Atomic Motion in Enzymatic Catalysis. Biochemistry, 2001, 40, 853-860.
79. Shi, W. X.; Lewandowicz, A.; Tyler, P. C.; Furneaux, R. H.; Almo, S. C.; Schramm, V. L. Structural Comparisons of Human and Malarial Purine Nucleoside Phosphorylases, in preparation.